ADICON Clinical LaboratoryADICON Clinical Laboratory

Industry Updates

  • Boehringer Ingelheim files MAA with EMA for afatinib approval

    Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation posit...

  • Aeterna Zentari expects to file AEZS-130 NDA with FDA for adult growth hormone deficiency

    Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, A...

  • The key to treating AML may lie within FTL3 gene mutations

    The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at UCSF.Published this week in the journal Nature, the work val...

  • Genetic key to severe malaria resistance uncovered

    Researchers have identified two genetic variants linked with human resistance to severe malaria.
    The team believes that the single nucleotide polymorphisms (SNPs), located within the ATP2B4 gene on chromosome 1 (rs4951074) and near MARVELD3 on chromosome 16 (rs2334880), may confer resistan...

  • Researchers reveal possible drug targets to combat anthrax

    A trawl of the genome of the deadly bacterium Bacillus anthracis has revealed a clutch of targets for new drugs to combat an epidemic of anthrax or a biological weapons attack. The targets are all proteins that are found in the bacteria but not in humans and are involved in diverse bacterial proc...

  • ADICON attended AACC 2012, together with sister companies AconLab and Huitu

    ADICON attended AACC 2012, together with sister companies AconLab and Huitu
    The world’s largest gathering of In vitro diagnostics, annual meet...
  • Three alternative diabetes markers found

    Experts have identified three alternative biomarkers that may be useful for picking up on diabetes risk.
    In a study of individuals who were initially free of the condition, baseline levels of fructosamine, glycated albumin, and 1,5 anhydroglucitol (1,5-AG) strongly predicted diabetes.

  • Cepheid launches new Xpert BCR-ABL Monitor test

    Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive o...

  • Vorinostat drives HIV from hiding

    The addition of vorinostat to current antiretroviral therapy (ART) regimens can potentially help to eradicate hidden pockets of dormant human immunodeficiency virus (HIV), according to study results published in Nature.

    Persistent reservoirs of dormant HIV often remain despite years of tr...

  • Lung cancer patients can be screened for ALK-inhibitor suitability

    Anaplastic lymphoma kinase (ALK) gene status in patients with lung adenocarcinoma can be determined non-invasively using circulating tumor cells (CTCs), research shows.
    Since patients with altered ALK show "an outstanding favourable response" to targeted inhibition, the findings ...

Page 3 of 4 << Previous 1 2 3 4 Next >>